Anaheim Bio Launches With Funding for Crystal Disease Drug
Anaheim Bio launched on November 5 with an oversubscribed €40 million Series A to advance ANA-1, an extracellular pyrophosphate-lowering small molecule for calcium pyrophosphate deposition disease. The company says it was spun out of…
